Pierre-Maxence Vaysse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pierre-Maxence Vaysse has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Balluff
M4I, The Maastricht MultiModal Molecular Imaging Institute, Maastricht University, Maastricht, The Netherlands
1 shared publication - Ron M. A. Heeren
The Maastricht MultiModal Molecular Imaging (M4I) Institute, Division of Imaging Mass Spectrometry (IMS), Maastricht University, Maastricht, The Netherlands
1 shared publication - Tiffany Porta Siegel
Maastricht MultiModal Molecular Imaging (M4I) Institute, Division of Imaging Mass Spectrometry, Maastricht University, Maastricht, The Netherlands
1 shared publication
Latest Publications
- Top Cited Papers
- 12 June 2017
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 142 (15) , 2690-2712
Mass spectrometry imaging for clinical research – latest developments, applications, and current limitations
Mass spectrometry is being used in many clinical research areas ranging from toxicology to personalized medicine. Of all the mass spectrometry techniques, mass spectrometry imaging (MSI), in particular, has continuously grown towards clinical acceptance. Significant technological and methodological improvements have contributed to enhance the performance of MSI recently, pushing the limits of throughput, spatial resolution, and sensitivity. This has stimulated the spread of MSI usage across various biomedical research areas such as oncology, neurological disorders, cardiology, and rheumatology, just to name a few. After highlighting the latest major developments and applications touching all aspects of translational research (i.e. from early pre-clinical to clinical research), we will discuss the present challenges in translational research performed with MSI: data management and analysis, molecular coverage and identification capabilities, and finally, reproducibility across multiple research centers, which is the largest remaining obstacle in moving MSI towards clinical routine.
- 12 June 2017
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 142 (15) , 2690-2712
Top Cited PapersMass spectrometry imaging for clinical research – latest developments, applications, and current limitations
Mass spectrometry is being used in many clinical research areas ranging from toxicology to personalized medicine. Of all the mass spectrometry techniques, mass spectrometry imaging (MSI), in particular, has continuously grown towards clinical acceptance. Significant technological and methodological improvements have contributed to enhance the performance of MSI recently, pushing the limits of throughput, spatial resolution, and sensitivity. This has stimulated the spread of MSI usage across various biomedical research areas such as oncology, neurological disorders, cardiology, and rheumatology, just to name a few. After highlighting the latest major developments and applications touching all aspects of translational research (i.e. from early pre-clinical to clinical research), we will discuss the present challenges in translational research performed with MSI: data management and analysis, molecular coverage and identification capabilities, and finally, reproducibility across multiple research centers, which is the largest remaining obstacle in moving MSI towards clinical routine.